TAS::75 0849::TAS; SBIR TOPIC 255, PHASE II "A STRADOBODY DIRECTED AGAINST LOW E

背景资料Rituxan和Herceptin是价值数十亿美元的产品，对淋巴瘤和乳腺癌有用。然而，某些人群的重大医疗需求仍未得到满足，例如复发性惰性非霍奇金淋巴瘤、HER2 IHC 2+患者以及FcgR3a 158F/F多态患者的治疗。这项合同提案旨在：a)产生一种新型的抗CD20或抗HER2 neu化合物，该化合物将进入临床试验，并被证明比目前市场上销售的抗体化合物具有优势，以及b)建立一种治疗癌症的新方法。

Background Information ¿ Rituxan¿ and Herceptin¿ are multi-billion dollar products that are useful in lymphoma and breast cancer. However, significant unmet medical need persists for certain populations such as recurrent indolent NHL, HER2 IHC 2+ patients, and treatment of patients with the FcgR3a 158 F/F polymorphism. This contract proposal is designed to: a) generate a novel anti-CD20 or anti-HER2 neu compound that will advance towards clinical trial and prove to have advantages over the currently marketed antibody compound, and b) establish a new therapeutic approach to cancer.